GH Stock Chart & Stats
$2784.00
$0.00(0.00%)
At close: 4:00 PM EDT
$2784.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$955.36 - $2,877.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$421.80B
Enterprise Value$20.58K
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)$1.70B
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Oct 29, 2026EPS Estimate
-12.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding134,196,170
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio4.56
Price to Book (P/B)-128.95
Price to Sales (P/S)13.04
P/FCF Ratio-54.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3,491.21Price Target Upside25.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)-56.61
Revenue Forecast (FY)$24.08B
Bulls Say, Bears Say
Bulls Say
Revenue And Volume GrowthRapid revenue and test-volume growth indicates expanding adoption across Oncology and Screening. Higher guidance also suggests commercial execution is translating into durable demand, while greater scale can strengthen operating leverage and broaden Guardant’s position in precision oncology.
Regulatory And Coverage ProgressFDA approvals, guideline inclusion, and expanding payer access improve the clinical and commercial foundations for Guardant’s tests. These milestones can support physician adoption, broaden eligible patients, enhance workflow economics, and reinforce the company’s competitive position.
Biopharma Platform And Data AssetA large proprietary genomic and epigenetic dataset supports Guardant’s biopharma services, trial activities, and real-world evidence offerings. Record segment revenue indicates commercial relevance, while the expanding data asset may deepen customer value and create durable platform advantages.
Bears Say
Persistent Losses And Cash BurnGuardant remains dependent on external funding while its diagnostics platform scales, because operations and investment continue to consume substantial cash. Persistent losses reduce financial resilience and make the path to company-wide self-funding dependent on successful growth and margin execution.
Leverage And Negative EquityHigh debt combined with negative equity limits financial flexibility and increases the consequences of execution shortfalls. A strained balance sheet can constrain investment choices, amplify refinancing exposure, and make it harder to absorb sustained losses while the company pursues expansion.
Scaling Costs And Reimbursement UncertaintyGuardant is investing heavily in Screening commercialization while key reimbursement and pricing outcomes remain unresolved. Elevated expenses can prolong losses, and delayed or less favorable coverage could limit realized prices, slowing the conversion of strong test growth into sustainable profitability.
Guardant Health News
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $955.36 and its highest was $2877.00 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $421.80B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is Oct 29, 2026 which is in 30 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Jul 30, 2026. The company reported -$15.221 earnings per share for the quarter, missing the consensus estimate of -$12.887 by -$2.334.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -12.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 134,196,170 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$15.221 in its last earnings report, missing expectations of -$12.887. Following the earnings report the stock price went up 7.49%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in MX:GH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3,491.21 (25.40% Upside)
$3,491.21 (25.40% Upside)
Blogger Sentiment
Bullish
MX:GH Sentiment 85%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $1.2B over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
194.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
43.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Guardant Health
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
GH Company Deck
GH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: broad-based, high-double-digit revenue and volume growth, major FDA approvals (Guardant360 Liquid CDx and a higher-throughput Shield workflow), guideline inclusion and a major payer (UnitedHealth) coverage decision for Shield, record Biopharma results, meaningful margin and cost-per-test improvement initiatives, and expanded commercial reach. Offsetting these positives are elevated operating expenses and investments (S&M and CapEx) to scale Screening, a modest adjusted EBITDA loss and increased free cash flow burn, and outstanding reimbursement/pricing uncertainties (ADLT timing, MolDX/Reveal coverage, USPSTF). On balance, the positive commercial, regulatory and margin trends materially outweigh the near-term cost and reimbursement risks, though execution and payer outcomes remain key near-term sensitivities.View all MX:GH earnings summariesGH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
GH Stock 12 Month Forecast
Average Price Target
$3,491.21
▲(25.40% Upside)